Prevalence of Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitor Prescribing in Patients with Type 2 Diabetes Mellitus and Reduced Estimated Glomerular Filtration Rate.

Kayla Chonko, Giavanna Russo-Alvarez, Diana Isaacs, Lu Wang, Amanda Soric

Open access · diamondAbstract read

In one paragraph

Article in Innovations in pharmacy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

0.4field-weighted citation impact, top 34% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Kayla ChonkoPharmacy Department, Cleveland Clinic, Cleveland, Ohio, 9500 Euclid Ave, Cleveland, Ohio, 44195.

Giavanna Russo-AlvarezPharmacy Department, Cleveland Clinic, Cleveland, Ohio, 9500 Euclid Ave, Cleveland, Ohio, 44195.

Diana IsaacsPharmacy Department, Cleveland Clinic, Cleveland, Ohio, 9500 Euclid Ave, Cleveland, Ohio, 44195.

Lu WangQuantitative Health Sciences Department, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.

Amanda SoricPharmacy Department, Cleveland Clinic, Cleveland, Ohio, 9500 Euclid Ave, Cleveland, Ohio, 44195.

Cleveland Clinic · USCleveland Clinic Lerner College of Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sodium glucose cotransporter 2 (SGLT-2) inhibitors have demonstrated benefit in people with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), including slowing the progression of CKD and lowering the risk of kidney failure and death. Despite this evidence, literature suggests SGLT-2 inhibitors are underutilized in this population. To assess prescribing practices and identify potential variables predictive of SGLT-2 inhibitor prescribing, a non-interventional, retrospective, cross-sectional study was conducted in patients with T2DM and reduced estimated glomerular filtration rate (eGFR). The primary outcome compared prevalence of SGLT-2 inhibitor prescribing in patients with T2DM and eGFR of 30-44 mL/min/1.73m

Indexed as

chronic kidney disease (CKD)prescribing prevalencesodium-glucose cotransporter-2 (SGLT-2) inhibitorsType 2 diabetes

Identifiers

PMID38025173

DOI10.24926/iip.v14i2.5456

PMCPMC10653713

OpenAlexW4382318832

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.